Can a culturally tailored program help hispanics beat fatty liver disease?
NCT ID NCT07199491
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a lifestyle program called Healthy Liver/Hígado Sano for Hispanic patients with metabolic-dysfunction associated steatotic liver disease (MASLD), also known as fatty liver disease. The program includes education sessions and family support to help participants lose weight and improve liver health. Researchers will check if the program is practical and liked by patients, with 64 adults expected to join.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 64 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Self-reported Hispanic/Latino * Have been diagnosed with MASLD * Be an adult \>= 18 years of age * Able to speak English or Spanish * Have a working telephone number * Have access to internet, either on their phone, at home or at some other location convenient to the participant * Have a family member willing to attend all sessions Exclusion Criteria: * Taking a GLP-1 receptor agonist or dual agonist at the time of enrollment, or plans to being taking one in the next 6 months
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metabolic dysfunction-associated steatotic liver disease (masld) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can big data unmask hidden clusters of cardiometabolic disease?
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Navy beans take on fatty liver: a diet swap put to the test
- New drug miricorilant tested for fatty liver disease safety
- Natural compound SAMe tested to block liver cancer in High-Risk patients
- New drug combo targets genetic fatty liver in Mid-Stage trial